Relapsed Pediatric AML Clinical Trial
Official title:
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.
Outcome of pediatric cancer has been improved substantially over the past few decades, but
the prognosis of relapsed/refractory pediatric cancer still remains poor. Advances in genomic
technologies have improved the ability to detect diverse somatic and germline genomic
aberrations of cancer patients, and it has been incorporated in the clinical management of
cancer.
Samsung Genomic Institute developed a targeted next-generation sequencing (NGS) platform,
CancerSCAN™, which can detect clinically significant genomic aberrations of tumors. In this
study, tumor samples of refractory/relapsed pediatric cancer patients will be tested with
CancerSCAN™ and the patients will receive combination chemotherapy with matched
single-targeted agent or multi-targeted receptor tyrosine kinase inhibitor according to the
result of CancerSCAN™.
I. Relapsed/refractory solid tumor
- Perform CancerSCAN™ at enrollment
- Conventional chemotherapy (ifosfamide, carboplatin, etoposide) with matched
single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib,
pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or
multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to
the result of CancerSCAN™
II. Relapsed/refractory AML
- Perform CancerSCAN™ at enrollment
- Conventional chemotherapy (fludarabine, cytarabine) with matched single-targeted agent
(axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib,
ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted
receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of
CancerSCAN™
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04033627 -
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
|
N/A | |
| Completed |
NCT04562792 -
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
|
Phase 2 | |
| Withdrawn |
NCT05622591 -
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
|
Phase 1 | |
| Approved for marketing |
NCT03245424 -
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
|